使用免疫信息学方法开发使用癌胚抗原和IGF-1R作为免疫刺激剂的癌症疫苗
Louis Odinakaose Ezediuno1, Michael Asebake Ockiya2, Luqman Oluwaseun Awoniyi3
1Department of Microbiology, University of Benin, Benin City, Nigeria.
Korean journal of clinical oncology
|May 9, 2025
概括
这项研究开发了一种针对癌胚抗原 (CEA) 和胰岛素样生长因子-1受体 (IGF-1R) 的新型多基皮托普疫苗,用于预防结肠直肠癌 (CRC). 该疫苗表现出强大的结合性和强大的免疫反应对CRC生物标志物的潜力.
科学领域:
- 免疫信息学是指免疫信息学.
- 疫苗设计 疫苗设计
- 计算生物学 计算生物学
背景情况:
- 结肠直肠癌 (CRC) 是一个重大的全球健康挑战,推动了创新的预防和治疗策略的需求.
- 癌胚抗原 (CEA) 和胰岛素样生长因子-1受体 (IGF-1R) 是关键的生物标志物,与CRC进展有关.
研究的目的:
- 设计和计算评估一种针对结直肠癌的CEA和IGF-1R的新型多皮托普疫苗.
- 预测拟议的疫苗结构的免疫性和结构完整性.
主要方法:
- 生物信息检索和CEA和IGF-1R蛋白序列的调整.
- 在 T 细胞 (CTL,HTL) 和 B 细胞表位,抗原性和过敏原性的 In silico 预测.
- 二级和三级结构预测,其次是分子对接到Toll-like受体4 (TLR4).
主要成果:
- 确定CEA和IGF-1R具有高度抗原性和非过敏性,适合引起免疫反应.
- 预测的疫苗结构显示了有利的二级和三级构造,具有高可靠性验证.
- 分子对接揭示了具有较低结合能量的稳定结合复合体,表明了强大的相互作用.
结论:
- 在 silico 分析支持这个多基皮托普疫苗的潜力,作为结直肠癌的有前途的预防策略.
- 需要进一步的实验验证,以确认这种候选疫苗的疗效.
相关概念视频
Cancer Vaccines
307
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
307
Tumor Immunotherapy
441
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
441


